View New Articles By
Damon Runyon Fellow Lindsay M. LaFave, PhD, and colleagues at Massachusetts Institute of Technology and Harvard University, discovered that elevated levels of a protein called RUNX2 in human lung tumors predict a worse prognosis—a finding which could lead to new diagnostics and drug targets.
Fifteen early career scientists from across the country will receive grants totaling nearly $3.5 million to pursue brave and bold cancer research. The recipients of the Damon Runyon Fellowship are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.
Damon Runyon scientists Vinod P. Balachandran, MD, and Lydia Finley, PhD, have received the 2020 Pershing Square Sohn Prize for Young Investigators in Cancer Research. Recipients receive $200,000 per year for up to three years and opportunities to present their work to scientific and business audiences, helping to bridge the gap between the academic and business communities.
The Damon Runyon Cancer Research Foundation has named two outstanding young scientists as recipients of the Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $500,000 to help address a critical shortage of funding for pediatric cancer research.
When cancer cells escape their primary tumor and move to the fluid and tissues surrounding the brain and spinal cord—a condition called leptomeningeal metastasis—the result is devastating. Now, Damon Runyon Clinical Investigator Adrienne A. Boire, MD, PhD, and colleagues at Memorial Sloan Kettering have discovered how these rogue cells are able to survive in the barren environment of the cerebral spinal fluid (CSF) and suggest a possible strategy for treatment.
A new publication from Damon Runyon Physician-Scientist Jonathan E. Shoag, MD, and colleagues at Weil Cornell Medicine shows that PSA screening has benefits beyond lowering prostate cancer death risk, such as prevention of metastatic disease and the impaired quality of life associated with its treatment. The researchers suggest that the balance of benefits and harms of screening may be more favorable than previously recognized.
Damon Runyon chats with Former Clinical Investigator Jakob Dupont, MD, about his pioneering path to develop cellular immunotherapies and other innovative oncology drugs.
Damon Runyon Physician-Scientist Andrew L. Ji, MD, and colleagues at Stanford University School of Medicine have discovered a population of specialized cells living at the edges of a tumor that potentially guide the metastasis of skin cancer and help it evade the body’s immune system.
The American Association for Cancer Research (AACR) has presented the 2020 AACR-Joseph Burchenal Award for Outstanding Achievement in Clinical Cancer Research to Damon Runyon alum Jedd D. Wolchok, MD, PhD. This award recognizes Dr. Wolchok for his leadership in the groundbreaking clinical development of immunotherapy drugs called checkpoint inhibitors for treating cancer.
Last week, the Food and Drug Administration (FDA) approved the HPV vaccine for the prevention of head and neck cancers. This is welcome news to Former Damon Runyon Clinical Investigator Maura L. Gillison, MD, PhD, who has been fighting for this approval for over a decade.
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
